Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Launching the Era of Melanoma Survivorship: Defining Benchmarks in Quality of Life Inclusive of Mental Health (QOL-MH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Contact:
- Deanna Hofschulte
- Phone Number: 507-255-2972
-
Principal Investigator:
- Shawna L. Ehlers, PhD, LP
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18-years
- Stage III-IV melanoma and =< 2 month duration of this diagnosis
- Able to read English sufficient to complete survey, informed consent
Exclusion Criteria:
- Does not meet inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aim 1 (QOL-MH)
Patients complete QOL-MH questionnaires at baseline and 3, 6, 9, 12, 18, and 24-months post-stage III-IV diagnosis.
Patients living in Minnesota, Iowa, or Wisconsin may also optionally participate in aim 2.
|
Ancillary studies
Complete QOL-MH questionnaires
|
|
Experimental: Aim 2 arm I (CBT-C)
Patients attend CBT-C sessions once a week for 6 weeks in the absence of unacceptable toxicity.
|
Ancillary studies
Complete QOL-MH questionnaires
Attend CBT-C sessions
Other Names:
|
|
Active Comparator: Aim 2 arm II (SOC)
Patients receive SOC for 6 weeks in the absence of unacceptable toxicity.
|
Receive SOC
Other Names:
Ancillary studies
Complete QOL-MH questionnaires
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in FACT-M total score (Aim 1)
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Functional Assessment of Cancer Therapy - Melanoma (FACT-M) is a 52-item questionnaire used to measures quality of life (QoL) in melanoma cancer patients.
Responses to each item are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much).
Scores range from 0-108 with higher scores indicating better quality of life.
For this study, 8 items have been omitted, so the number of items is 44, with total scores ranging from 0-176.
Descriptive statistics will be used to tabulate and graph the observed total scores and the change from baseline total scores over time.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in FACT-ICM total score (Aim 1)
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator (FACT-ICM) is a 25-item subscale that measures symptom burden and health-related quality of life (HRQoL) over the past 7 days in patients receiving immune checkpoint inhibitors.
Responses to each question are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much).
Scores range from 0-100 with higher scores indicating greater symptom burden and poorer quality of life.
Descriptive statistics will be used to tabulate and graph the observed total scores and the change from baseline total scores over time.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in Impact of Events Scale-Revised (IES-R) score (Aim 1)
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Impact of Event Scale-Revised (IES-R) is a 22-item self-report measure designed to assess subjective distress related to stressful life events.
The IES-R consists of 22 items for which participants rate how distressing each difficulty has been during the past 7 days with regard to their cancer diagnosis.
Responses are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely).
Scores range from 0-88 with higher scores indicating greater distress.
Descriptive statistics will be used to tabulate and graph the observed total scores and the change from baseline total scores over time.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in IES-R score (Aim 2)
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Impact of Event Scale-Revised (IES-R) is a 22-item self-report measure designed to assess distress related to stressful life events.
The IES-R consists of 22 items which participants rate distress over the past 7 days with regard to their cancer diagnosis.
Responses are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely).
Scores range from 0-88 with higher scores indicating greater distress.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in PHQ-8 score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Patient Health Questionnaire-8 (PHQ-8) is a brief, self-report tool used to screen for and measure the severity of depression by asking about 8 depressive symptoms over the past two weeks, scoring from 0 (not at all) to 3 (nearly every day) for each, with total scores indicating severity (e.g., 0-4 minimal, 10-14 moderate) and a score of 10 or more often suggesting major depression.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in GAD-7 Anxiety score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The General Anxiety Disorder 7-item (GAD-7) scale is used to assess symptoms and feelings of anxiety over the past two weeks.
The GAD-7 consists of 7 questions answered on a scale of 0 (not at all) to 3 (nearly every day).
The total score ranges from 0 to 21 where 0 indicates no anxiety, 1-4 indicates minimal anxiety, 5-9 indicates mild anxiety, 10-14 indicates moderate anxiety, and 15-21 indicates severe anxiety.
If patients indicate any problems they are asked to indicate how difficult the problems have made daily life: not difficult at all, somewhat difficult, very difficult, or extremely difficult.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in PSQI score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Pittsburgh Sleep Quality Index (PSQI)measures the severity of sleep disturbances.
Possible scores range from 0 to 21 with higher scores indicating a worse outcome/more severe symptoms of sleep disturbance.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in PROMIS: Fatigue score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Patient-Reported Outcomes Measurement Information System (PROMIS): Fatigue questionnaire, a subscale of the PROMIS-29, measures fatigue and related symptoms over the past seven days.
It consists of four items rated on a scale of 1(not at all) to 5 (very much).
A higher score indicates greater experience of fatigue.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in PROMIS: Pain Interference score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The PROMIS: Pain Interference questionnaire, a subscale of the PROMIS-29, is used to assess pain interference in daily life over the past seven days.
It consists of four items rated on a scale of 1(not at all) to 5 (very much).
A higher score indicates greater levels of pain interference.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in COST-FACIT score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COSTFACIT) measures financial toxicity among cancer patients.
This measure reflects five themes of financial toxicity which include: financial, resource, affect, coping, and effect on family.
It consists of 12 questions, each answered on a scale of 0 (not at all) to 5 (very much), with higher scores indicating greater financial toxicity.
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
|
Change in MEPS score
Time Frame: Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
The Medical Expenditures Survey (MEPS) measures the financial impact of cancer, its treatment, or the lasting effects of that treatment.
It consists of 5 multiple choice questions, including free text/ / fill-in options where appropriate.
Results are reported descriptively. .
|
Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shawna L. Ehlers, PhD, LP, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Skin Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Skin and Connective Tissue Diseases
- Melanoma
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Behavior Therapy
- Psychotherapy
- Behavioral Disciplines and Activities
- Guidelines as Topic
- Quality Assurance, Health Care
- Standard of Care
- Cognitive Behavioral Therapy
- Practice Guidelines as Topic
Other Study ID Numbers
Other Study ID Numbers
- 25-007199 (Mayo Clinic Institutional Review Board)
- HT9425-25-1-0802 (Other Grant/Funding Number: Department of Defense)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.